%20--%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20100.6%2073.7'%20style='enable-background:new%200%200%20100.6%2073.7;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill:%23AF001E;}%20.st1{fill:%23FFFFFF;}%20%3c/style%3e%3cg%3e%3crect%20class='st0'%20width='100.6'%20height='73.7'/%3e%3cpath%20class='st1'%20d='M25.2,36.3l-0.5,2.3c-0.2,0.7-0.2,1-0.2,1.2c0,0.5,0.2,1,0.5,1.6L31.5,53c0.5,0.9,1,1.3,2.3,1.3h5.9%20c0.8,0,1.7-0.5,0.8-1.8l-7.9-13.1c2.7-1.7,5.6-4.1,5.6-9.3c0-6.8-3.8-10.6-12.2-10.6H13.9c-1.1,0-1.4,0.4-1.4,1.5v32%20c0,1.1,0.3,1.5,1.4,1.5h5c1.1,0,1.4-0.4,1.4-1.5V26h5.2c3.3,0,4.8,1.2,4.8,4.2c0,2.8-1.2,3.6-2.5,4.2C26.3,35,25.7,34.3,25.2,36.3z%20'/%3e%3cpath%20class='st1'%20d='M45.9,48.8L45.3,53c-0.1,0.8,0.3,1.1,1,1.2c1.6,0.2,5.5,0.5,9.4,0.5c8.6,0,14.9-2.8,14.9-10.9%20c0-4.7-2.1-8.3-9.2-10.1l-4-1c-2.7-0.7-4-1.6-4-3.6c0-2.8,2.6-3.4,5.1-3.4c3.4,0,6.8,0.3,8.1,0.4c1.4,0.1,1.8-0.1,2-1.2l0.7-4.1%20c0.1-0.8-0.3-1.1-1-1.2c-1.6-0.2-5-0.5-9.4-0.5c-9,0-13.3,3.9-13.3,10.1c0,5.6,3,8.9,8.3,10.3l4,1c3.3,0.9,4.7,1.8,4.7,3.9%20c0,3-2.1,3.6-7.1,3.6c-2.3,0-6.2-0.3-7.6-0.4C46.5,47.4,46.1,47.6,45.9,48.8z'/%3e%3cpath%20class='st1'%20d='M79.4,52.9c0,1.1,0.3,1.5,1.4,1.5h5c1.1,0,1.4-0.4,1.4-1.5v-32c0-1.1-0.3-1.5-1.4-1.5h-5%20c-1.1,0-1.4,0.4-1.4,1.5V52.9z'/%3e%3c/g%3e%3c/svg%3e)
La Commissione della concorrenza (COMCO) ha posto fine a un’intesa illecita tra diverse aziende farmaceutiche che, per 14 anni (dal 2005 al 2019), si sono accordate sui prezzi e sulla ripartizione delle quote di mercato di un principio attivo: la scopolamina-N-butilbromuro (SNBB), utilizzata per la produzione di farmaci antispastici contro il mal di pancia.
L’indagine della COMCO ha rivelato che le aziende Boehringer Ingelheim, Alkaloids of Australia, Alkaloids Corporation, Alchem, C2 PHARMA, Linnea e Transo-Pharm hanno manipolato il mercato, scambiandosi informazioni sensibili e fissando prezzi minimi di vendita.
Si tratta della prima volta che la COMCO sanziona un cartello nel settore dei principi attivi farmaceutici. Le multe totali ammontano a circa 600’000 franchi, ridotte grazie al programma di clemenza: C2 PHARMA ha ottenuto l’immunità totale per aver rivelato l’intesa, mentre Transo-Pharm e Linnea hanno beneficiato di riduzioni parziali.
Comco, no all'acquisizione di Quickmail
Telegiornale 19.01.2024, 12:30
La COMCO ha condotto 27 indagini nel 2023
Telegiornale 30.04.2024, 12:30
Entra nel canale WhatsApp RSI Info
Iscriviti per non perdere le notizie e i nostri contributi più rilevanti
https://whatsapp.com/channel/0029Vat6p4zL2ATyO8IRFJ2C
%20--%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%20138.2%2048'%20style='enable-background:new%200%200%20138.2%2048;'%20xml:space='preserve'%3e%3cstyle%20type='text/css'%3e%20.st0{fill-rule:evenodd;clip-rule:evenodd;fill:%23AF001E;}%20.st1{fill-rule:evenodd;clip-rule:evenodd;fill:%23FFFFFF;}%20%3c/style%3e%3cpath%20class='st0'%20d='M0,48h138V0H0V48z'/%3e%3cpath%20class='st1'%20d='M9.3,31.7l-0.4,2.7C8.8,35,9,35.2,9.5,35.3c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3s-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3C11.8,12.4,9,14.9,9,19c0,3.6,2,5.8,5.4,6.7%20l2.6,0.7c2.1,0.6,3,1.2,3,2.5c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3C9.6,30.9,9.4,31,9.3,31.7'/%3e%3cpath%20class='st1'%20d='M36.4,23.6l-0.3,1.5C36,25.4,36,25.6,36,25.9c0,0.4,0.1,0.8,0.4,1.1l4.2,7.6c0.1,0.3,0.3,0.5,0.6,0.7%20c0.3,0.2,0.6,0.2,0.9,0.2h3.8c0.5,0,1.1-0.3,0.5-1.2l-5.1-8.6c1.7-1.1,3.6-2.6,3.6-6.1c0-4.4-2.5-6.9-7.9-6.9h-7.8%20c-0.7,0-0.9,0.2-0.9,1v20.8c0,0.7,0.2,1,0.9,1h3.2c0.7,0,0.9-0.2,0.9-1V16.8h3.3c2.1,0,3.1,0.8,3.1,2.8c0.1,0.6,0,1.2-0.3,1.6%20c-0.3,0.5-0.7,0.9-1.3,1.1C37.1,22.7,36.8,22.3,36.4,23.6z'/%3e%3cpath%20class='st1'%20d='M66.1,34V22.7c0-0.7-0.2-1-0.9-1h-5.8c-0.7,0-0.9,0.2-0.9,1v2.5c0,0.7,0.2,0.9,0.9,0.9h1.7v5%20c-0.6,0.1-1.1,0.1-1.7,0.1c-4.8,0-6-3.1-6-7.4c0-5.4,2-6.8,6.5-6.8c1.3,0,3.1,0.1,4.1,0.2c1,0.1,1.2,0,1.3-0.8l0.4-2.5%20c0.1-0.7,0-1-0.8-1.1c-1.8-0.2-3.6-0.3-5.4-0.2c-8.2,0-11.6,4.3-11.6,11.3s2.7,11.9,11.3,11.9c2,0.1,4,0,6-0.4%20C65.9,35.2,66.2,34.9,66.1,34'/%3e%3cpath%20class='st1'%20d='M74.9,31.7l-0.4,2.7c-0.1,0.5,0.2,0.7,0.6,0.8c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3s-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3c-5.8,0-8.6,2.6-8.6,6.6%20c0,3.6,2,5.8,5.4,6.7l2.6,0.7c2.1,0.6,3,1.2,3,2.6c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3C75.3,30.8,75,30.9,74.9,31.7'/%3e%3cpath%20class='st1'%20d='M93.1,31.7l-0.4,2.7c-0.1,0.5,0.2,0.7,0.6,0.8c2,0.2,4,0.3,6.1,0.3c5.6,0,9.7-1.8,9.7-7.1c0-3.1-1.3-5.4-6-6.6%20l-2.6-0.7c-1.8-0.5-2.6-1-2.6-2.3c0-1.9,1.7-2.2,3.3-2.2c2.2,0,4.4,0.2,5.3,0.2c0.9,0.1,1.2,0,1.3-0.8l0.4-2.6c0-0.1,0-0.2,0-0.3%20c0-0.1-0.1-0.2-0.1-0.3c-0.1-0.1-0.1-0.1-0.2-0.2c-0.1,0-0.2-0.1-0.3-0.1c-2-0.2-4.1-0.3-6.1-0.3c-5.8,0-8.6,2.6-8.6,6.6%20c0,3.6,2,5.8,5.4,6.7l2.6,0.7c2.1,0.6,3,1.2,3,2.6c0,2-1.3,2.3-4.6,2.3c-1.5,0-4-0.2-4.9-0.3S93.1,30.9,93.1,31.7'/%3e%3cpath%20class='st1'%20d='M120.2,23.6l-0.3,1.5c-0.1,0.3-0.1,0.5-0.1,0.8c0,0.4,0.1,0.8,0.3,1.1l4.2,7.6c0.1,0.3,0.3,0.5,0.6,0.7%20c0.3,0.2,0.6,0.2,0.9,0.2h3.8c0.5,0,1.1-0.3,0.5-1.2l-5.1-8.6c1.7-1.1,3.7-2.7,3.7-6.1c0-4.4-2.5-6.9-7.9-6.9H113%20c-0.7,0-0.9,0.2-0.9,1v20.8c0,0.7,0.2,1,0.9,1h3.2c0.7,0,0.9-0.2,0.9-1V16.8h3.3c2.1,0,3.1,0.8,3.1,2.8c0.1,0.6,0,1.2-0.3,1.6%20c-0.3,0.5-0.7,0.9-1.3,1.1C120.9,22.7,120.6,22.3,120.2,23.6'/%3e%3c/svg%3e)